Martin Drysdale, Ph.D.
Martin Drysdale is the director of the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard.
From the end of 1989 to 1991, Drysdale was a Parke-Davis Neuroscience Post-Doctoral Research Fellow at the PD site in Cambridge, UK, and then spent six years at Wellcome and GlaxoWellcome in the UK working on projects in the CNS and inflammatory therapeutic areas.
In 1997 he joined RiboTargets back in Cambridge, UK, then a biotech start-up company, to head up and develop the chemistry group there working on anti-infective targets. After surviving several rounds of mergers, acquisitions, and company name changes, he became director of chemistry & structural science and finally deputy director of research at Vernalis working in the oncology and CNS areas, with a particular interest in structure-based drug design and fragment-based methods of hit identification.
In January 2009, he became head of drug discovery at the Cancer Research UK Beatson Institute in Glasgow, Scotland, responsible for strategy and direction of the team with particular interest in novel, challenging targets such as protein-protein interactions with an emphasis on structure-guided drug discovery.
Drysdale received his B.Sc. and Ph.D. in chemistry from St. Andrews University in Scotland.